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REPLY
The letter from Dr. Aguiar-Souto and colleagues has been re-
viewed and their comments are very much appreciated. The
American College of Cardiology/American Heart Association
(ACC/AHA) 2005 guidelines for chronic heart failure ascribed a
class IIa, level of evidence A, recommendation to the adjunctive
use of isosorbide dinitrate/hydralazine to standard therapy in
patients with persistent symptoms of heart failure without a race
designation. The section of the guidelines addressing special
populations likewise ascribed a class IIa, level of evidence A,
recommendation to the use of combined vasodilator therapy in
addition to standard therapy in blacks with functional class III or
IV heart failure (1).
The rationale for this classification is based on the preponder-
ance of data demonstrating the benefit of combined vasodilator
therapy in symptomatic heart failure. The Vasodilator Heart
Failure Trials (V-HeFT I and V-HeFT II) demonstrated a mild
survival advantage for this regimen in V-HeFT I and improvement
in the important surrogate end points of exercise capacity and left
ventricular function in V-HeFT II. A subsequent retrospective
analysis of both trials demonstrated that the majority of the benefit
was seen in black patients, but the effect was not absent in the
non-black cohort (2). The significant results now demonstrated
in the African American Heart Failure Trial (A-HeFT) confirm
the advantage of this regimen (3). A strongly held opinion of the
guideline writing committee is that there are insufficient data to
assert that race alone is the operative variable that determines
responsiveness to this regimen. Thus, two clinical trials, V-HeFT
I and A-HeFT, demonstrate benefit in patients with symptomatic
heart failure, and a third trial, V-HeFT II, is consistent with a
favorable effect of vasodilator therapy in symptomatic heart failure.
A class IIa recommendation states that a given treatment or
intervention “is reasonable” and that the risk-benefit ratio is
decidedly favorable. Level A evidence for a class IIa recommen-
dation requires multiple positive data sources, but also allows for a
recommendation in favor of therapy despite incongruent data from
smaller datasets and retrospective analyses. Given multiple trials
demonstrating the benefit of combined vasodilator therapy in
diverse populations, the class recommendation appears reasonable
for both the general population and for blacks with symptomatic
heart failure, and the level of evidence is indeed consistent with the
several confirmatory trials.
The class IIb recommendation for the addition of an angioten-
sin receptor antagonist to already effective therapy is reasonable
based primarily on a morbidity-only advantage seen in the
CHARM-Added trial (4). The data regarding the use of nebivolol
had not been published during the deliberations of the guideline
writing committee; thus, they were not available to be incorporated
into the 2005 statement.
*Clyde W. Yancy, MD, FACC, FAHA, FACP
*UT Southwestern Medical Center
5323 Harry Hines Boulevard
Dallas, Texas 75390-9047
E-mail: clyde.yancy@utsouthwestern.edu
doi:10.1016/j.jacc.2006.04.019
REFERENCES
1. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 guideline
update for the diagnosis and management of chronic heart failure in the
adult. Available at: http://www.acc.org/clinical/guidelines/failure/
index.pdf. Accessed February 2006.
2. Carson P, Ziesche S, Johnson G, Cohn JN, for the Vasodilator-Heart
Failure Trial Study Group. Racial differences in response to therapy for
heart failure: analysis of the vasodilator-heart failure trials. J Card Fail
1999;5:178–87.
3. Taylor AL, Ziesche S, Yancy C, et al. for the African-American
Heart Failure Trial investigators. Combination of isosorbide dini-
trate and hydralazine in blacks with heart failure. N Engl J Med
2004;351:2049 –57.
4. McMurray JJ, Östergren J, Swedberg K, et al. for the CHARM
investigators and committees. Effects of candesartan in patients with
chronic heart failure and reduced left-ventricular systolic function taking
angiotensin-converting-enzyme inhibitors: the CHARM-Added trial.
Lancet 2003;362:767–71.
China’s Role in International Cardiology
Dr. DeMaria’s excellent editorial on international cardiology (1)
touches on several aspects that deserve further comments and
amplification from China’s point of view. After all, one of every
five persons on this planet lives in China (2).
First, the Journal of the American College of Cardiology (JACC) is
an excellent example of international cardiology (1). It may be of
interest to Dr. DeMaria to know that JACC is the second most
frequently cited foreign cardiologic journal referenced in articles
published in the Chinese Journal of Cardiology, the official cardiol-
ogy journal in China (2).
Second, Dr. DeMaria commented on the spectrum of car-
diovascular diseases among different countries worldwide.
While there are indeed such differences as illustrated by the
examples cited by Dr. DeMaria, the gaps are getting narrower.
For example, the metabolic syndrome has reached near epi-
demic proportions in the U.S., as Dr. DeMaria (1) men-
tioned. It has also become a problem in China where the
prevalence of metabolic syndrome is 13.3% (12.7% in male and
14.2% in female subjects) (3,4). In China, obesity—which has
become the nation’s newest health risk (5)—is the prin-
cipal reason for the increased prevalence of the metabolic
syndrome (3,4). It is a paradox to note that, whereas being
underweight is one of the major causes of death in rural China
(6), being overweight is one of the major concerns in urban
China (2).
Third, China is the most populous country in the world, with
over 1.3 billion people. Because of this enormous population
and a very low migration rate, it is an ideal country to conduct
clinical trials. As a matter of fact, the second largest trial of
treatment of acute myocardial infarction (AMI) in the world
and the largest clinical trial ever underaken in China, COM-
MIT (ClOpidogrel and Metoprolol in Myocardial Infarction
Trial), has just been published (7). The results of this mammoth
study, involving 45,852 patients in China, will undoubtedly
influence the treatment of AMI throughout the world in the
future.
Finally, I wish to echo what Dr. DeMaria said, namely that the
world is getting smaller. As my mentor, the late Dr. Paul D.
White, said, cardiology knows no international boundary and is
the world’s best goodwill ambassador (8).
224 Correspondence JACC Vol. 48, No. 1, 2006
July 4, 2006:219–25
